Floatz logo

CARVEDILOL

Cardiotoxicity

Abramson Cancer Center at Penn MedicineSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Cardiotoxicity cohort.

Asset / SponsorPhaseRating
POTASSIUM
Tufts Medical Center
Phase 3BB
Orlistat
University of British Columbia
Phase 4BB
VITAMIN D
Phase 3BB
Calcium
Phase 3BB
Acoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3BB

View all 36 →

Same molecule, other indications

CARVEDILOL is also rated in:

portal hypertensionDormant
BBB
Indicative ·
76 / 100
View asset →
esophageal varicesDormant
BBB
Indicative ·
73 / 100
View asset →
cirrhosis of liverDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →